WO2002026707A1

WO2002026707A1 - Novel compounds

Info

Publication number: WO2002026707A1
Application number: PCT/SE2001/002149
Authority: WO
Inventors: Styrbjörn BYSTRÖM; Stephen James; Charlotta Liljebris
Original assignee: Biovitrum Ab
Priority date: 2000-09-26
Filing date: 2001-09-26
Publication date: 2002-04-04
Also published as: AU2001292518A1

Abstract

The present invention is directed to compounds of formula (I), formula (Ia), and formula (Ib). Wherein each of R?1, R2, R3, R4, Ra, and Rb¿ has been defined herein. The invention is also directed to a process for the preparation, the use and pharmaceutical compositions comprising the compounds described above. These novel compounds are useful in therapy, particularly for the treatment of type 2 diabetes.

Description

NOVEL COMPOUNDS

Technical Field

The present invention is directed to novel compounds, to a process for their preparation, their use and pharmaceutical compositions comprising said novel compounds. These novel compounds are useful in therapy, particularly for the treatment of type 2 diabetes.

Background Phosphorylation on serine, threonine and tyrosine amino acid residues in downstream proteins forms the major output from growth factor and cytokine receptors, from which a cellular response is built. A large number of growth factor and cytokine- regulated protein tyrosine kinases (PTKs) have been identified which can be integral parts of receptor proteins or cytosolic molecules (Al-Obeidi, FA, Wu, JJ & Lam, KS, Biopolym. Pept. Sci. Sect. 47, 197-223). These serve to phosphorylate proteins on tyrosine residues within specific primary amino acid sequences which, when phosphorylated, act as docking points for proteins that contain SH2 domains. It is the docking of proteins to phosphorylated tyrosine residues that contributes to the activation of such proteins and the establishment of a signal transduction cascade. The overall output from signal transduction cascades is derived from the balance between phosphorylation and dephosphorylation of proteins. Phosphotyrosines are returned to their free acid form by the action of protein tyrosine phosphatases (PTPs) (Zhang, ZY (1998) Grit. Rev. Biochem. Mol. Biol., 33, 1-52). Whilst a large number of PTKs has been identified (Hunter, T (1994) Sem. Cell Biol. 5, 367-376), the number of PTPs identified to date is decidedly smaller (van Huijsduijnen, RH (1998) Gene 225, 1- 8). Despite the smaller number of enzymes in the PTP family available for investigation, a detailed understanding of the roles they play in signal transduction and disease has not been forthcoming. This is due in part to the lack of small molecule inhibitor molecules which are specific for members of the PTP family and which are permeable to the cell membrane and can thus be used in cell-based experiments. Furthermore, whilst experiments in transgenic animals can be and have been performed in which individual PTPs can be ablated, the effects of the loss of function of a specific enzyme maybe masked by compensation by other members of the PTP family. Thus, the availability of small molecule inhibitors of PTPs would be very useful to the study of this important family of enzymes.

A role for the PTP family of proteins in ontogeny and disease is now becoming clearer (Li, L & Dixon, JE (2000) Sem. Immunol. 12, 75-84). Thus, experiments with gene knockouts in transgenic animals has revealed that the motheaten phenotype of mice in which cells of the haematopoietic lineage undergo hyper-proliferation is due to the loss of normal SHPTP1 function (Schultz, LD, Schweitzer, PA, Rajan, TV, Yi, T & JJile, JN (1993) Cell 73, 1445-1454). Loss of function in the receptor-like subfamily of PTPs leads to conditions such as heightened and reduced sensitivity to insulin (Ren, J- M, Li, P-M, Zhang, W-R, Sweet, LJ, Cline, G, Shulman, GI, Livingston, JN & Goldstein, BJ (1998) Diabetes 47, 493-497), stunted growth and neurological disruption (Elchelby, M, Wagner, J, Kennedy, TE, Lanctot, C, Michaliszyn, E, Itie, A, Drouin, J & Tremblay, ML (1999) Nature Genet. 21, 330-333) and blockages in T cell maturation Kishihara, K, Penninger, J, Wallaca, NA, Kundig, TM, Kawai, K, Wakeham, A, Timms, E, Pfeffer K, Ohashi, PS & Thomas PL (1993) Cell 74, 143-156).

The recent descriptions of mice in which the PTP PTP1B had been disrupted revealed that loss of function of this enzyme leads to enhanced insulin sensitivity and resistance to the development of obesity, thus revealing a therapeutic need for the development of specific PTP inhibitors (Elchelby, M, Payette, P, Michaliszyn, E,

Cromlish, W, Collins, S, Loy, AL, Νormandin, D, Cheng, A, Himms.Hagen, J, Chan, CC, Ramachandran, C, Gresser, MJ, Tremblay, ML & Kennedy, BP (1999) Science 283, 1544-1548; Klaman, LD, Boss, O, Peroni, OD, Kim, JK, Martino, JL, Zablotny, JM, Moghal, Ν, Lubkin, M, Kim, Y-B, Sharpe, AH, Stricker-Krongrad, A, Shulman, GI, Νeel, BG & Kahn, BB (2000) Mol. Cell. Biol. 20, 5479-5489). The mechanism of insulin action depends critically upon the phosphorylation of tyrosine residues in several proteins in the insulin signaling cascade. PTPs that dephosphorylate these proteins are important negative regulators of insulin action. Therefore, the use of specific PTP inhibitors may therapeutically enhance insulin action. The anabolic effects of insulin are triggered through the activation of a variety of signal transduction cascades which lie downstream of the insulin receptor (Gustafson, T.A., Moodie, SA & Lavan, BE (1999) Rev. Physiol. Biochem. Pharmacol. 137, 71- 190). The varieties of signals that are activated by insulin are thought to contribute to the range of effects that insulin controls. However, each pathway is activated by a common series of biochemical reactions proximal to the insulin receptor. Thus, the insulin receptor undergoes autophosphorylation on tyrosine residues when activated by insulin, and also phosphorylates other proteins, in particular, the insulin receptor substrate proteins (IRSs). It has now become widely accepted that the resistance to insulin that is a feature of type 2 diabetes results in part from dysfunctions in signal transduction activated by the insulin receptor, in particular in steps early in the signaling cascades which are common to different pathways (Nirkamaki, A, Ueki, K & Kahn, R C (1999) J. Clin. invest. 103, 931-943; Kellerer, M, Lammers, R & Haring, H-U (1999) Exp. Clin. Endocrinol. Diabetes 107, 97-106).

The signals that emanate from the insulin receptor are switched off by the returning of the insulin receptor and other components of the signal transduction cascades to their basal, non-active states. For the insulin receptor and the IRS proteins, this is achieved by dephosphorylation of phosphotyrosine residues. It is now becoming clear that different PTPs may regulate the insulin receptor in different tissues, but the number of candidate enzymes which do this is small (Walchi, S., Curchod, M-L., Pescini Gobert, R., Arkinstall, S. & Hooft van Huijsduijnen, R. (2000) J. Biol. Chem. 275, 9792-9796). Thus, protein tyrosine phosphatase IB (PTP1B) appears to be the major negative regulator of the insulin receptor in muscle and liver tissues (see for example Elechelby, M, Payette, P, Michalszyn, E, Cromlish, W, Collins, S, Loy, AL, Νormandin, D, Cheng, A, Himms-Hagen, J, Chan, C-C, Ramachandran, C, Gresser, MJ, Tremblay, M & Kennedy, B P (1999) Science, 283, 1544-1548; Goldstein, BJ, Bittner- Kowalczyk, A, White, M F & Harbeck, M (2000) J. Biol. Chem. 275, 4283-4289). By contrast, PTP alpha may play a more dominant role in regulating the insulin receptor in adipose tissue (Calera, MR, Nallega, G & Pilch, PF (2000) J. Biol. Chem. 275 6308- 6312).

The development of type 2 diabetes is characterised by a protracted period of insulin resistance. In human subjects who are obese and insulin resistant, PTP protein concentrations are increased, which has led to the idea that elevations in the proteins contributes to the cause of the diabetic state (Ahmad, F, Azevedo, JL, Cortright, R, Dohm, G L & Goldstein, BJ (1997) J. Clin. Invest 100 449-458). The two most significantly elevated are PTP IB and LAR. Considering that loss of LAR activity is associated with insulin resistance and diabetes (Ren, J-M, Li, P-M, Zhang, W-R, Sweet, LJ, Cline, G, Shulman, GI, Livingston, JN & Goldstein, BJ (1998) Diabetes 47493- 497), these data support the concept that PTP1B is a major contributor to the insulin resistant state and that pharmacological inhibition of its activity may go some way towards pharmaceutically alleviating the condition. Indeed, the recent reports of the knockout mouse in which PTP1B has been ablated confirm that loss of PTP1B activity leads to enhancement of the metabolic effects of insulin (Elechelby, M, Payette, P, Michalszyn, E, Cromlish, W, Collins, S, Loy, AL, Normandin, D, Cheng, A, Himms- Hagen, J, Chan, C-C, Ramachandran, C, Gresser, MJ, Tremblay, M & Kennedy, B P (1999) Science, 283, 1544-1548; Klaman, LD, Ross, O, Peroni, OD, Kim, JK, Martino, JL, Zabolotny, JM, Moghal, N, Lubkin, M, Kim, Y-B, Sharpe, AH, Stricker-Krongrad, A, Shulman, GI, Neel, BG & Kahn, BB (2000) Mol. Cell. Biol. 20 5479-5489). Furthermore, inhibition of PTP1B with a specific small molecule has been reported to treat the symptoms of diabetes in the ob/ob mouse (Wrobel, J, Sredy, J, Moxham, C, Dietrich, A, Li, Z, Sawicki, DR, Seestaller, L, Wu. L, Katz, A, Sullivan, D, Tio, C & Zhang, Z-Y (1999) J. Med. Chem. 42 3199-3202).

The patent application with the publication no. WO 96/40113, discloses heterocyclic nitrogen containing compounds, such as nitropyridine or nitrothiazole, capable of inhibiting protein tyrosine phosphatase activity. Such molecules are disclosed as being useful to modulate or regulate signal transduction by inhibiting protein tyrosine phosphatase activity and to treat various disease states including diabetes mellitus.

WO 98/27065 discloses a class of compounds which are stated as being protein tyrosine phosphatase modulating compounds. These prior art compounds are however structurally distinct from the compounds claimed in the present patent application. WO 97/08934 discloses aryl acrylic acid compounds of a certain structure, which compounds are stated as having protein tyrosine protease modulating activity. Also these prior art compounds are however structurally distinct from the compounds claimed in the present patent application.

WO 99/58519 discloses certain phenyl oxo-acetic acid compounds. These compounds are stated as being useful in the treatment of metabolic disorders related to insulin resistance and hyperglycemia. Also these prior art compounds are however structurally distinct from the compounds claimed in the present patent application.

WO 99/58521 discloses the use of 1 l-aryl-benzo[b]naphtho[2,3-d]furan and 11- aryl-benzo[b]naphtho[2,3-d]thiophene compounds to inhibit protein tyrosine phosphatase activity. Such compounds are disclosed as being useful to modulate or regulate signal transduction by inhibiting protein tyrosine phosphatase activity and to treat various disease states including diabetes mellitus.

The preparation of the compound 4-hydroxy-3,3-dimethyl-2H-benzo[g]indole-

2,5(3H)-dione, said compound having the chemical structure

is disclosed by Siegfried Petersen et al. in Justus Liebigs Ann. Chem. (1972), 764, pp. 50-57. However, this prior art document does not disclose or even suggest that tins compound may have therapeutic activity, and particularly not in the diabetes area, such as type 2 diabetes. The object of the present invention was to provide novel compounds having improved advantages over drugs currently used for the treatment of type 2 diabetes. It should be appreciated that the wording "improved advantages" is not necessarily defined as more potent compounds, but as compounds having improved advantages overall, including but not limited to also improved selectivity and less side-effects.

Disclosure of the Invention The novel compounds according to the present invention are defined by the general formula I

wherein

R s (i) hydrogen;

(ii) linear or branched Cι-C₆ alkoxy;

(ii) -O-(Ci-C₆ alkyl)-Q, where the alkyl group may be linear or branched, and where Q is phenyl, naphthyl, or a heterocycle having from 5 and up to 10 ring atoms, where at least one of the ring atoms is an atom other than carbon, such as O, N, or S (e.g., R¹ can be

-O-methyl-phenyl, -O-ethyl-phenyl, or -O-propyl-phenyl); and (iii)

where n is an integer 1 or 2; and each of Q¹ and Q² is independently hydrogen or

Cι-C₆ alkyl where the alkyl group maybe linear or branched (e.g., methyl or ethyl); or

(iv)

O

II

CH₃— O— C— (CH₂) -0—

where n is an integer 1 or 2;

R² is (i) hydroxy;

(ii) linear or branched Cι-C₆ alkoxy (e.g., Cι-C₃ alkoxy) ; (iii) -O-CO-(Cι-C₆ alkyl) where the alkyl group may be linear or branched (e.g., -O-CO-methyl or -O-CO-methyl); or (iv) -O-CO-ρhenyl, or -O-CO-naphthyl; each of R³ and R⁴ is independently (i) Cι-C₆ alkyl, where the alkyl group may be linear or branched (e.g., methyl or ethyl); or (ii) cyclopentane, or cyclohexane; the compound 4-hydroxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dione being excluded.

The invention also features compounds of formula la

wherein each of R¹, R², R³ and R⁴ has been defined in formula I above, and wherein R^a is -CH₂-CO-(Cι-C₆ alkyl) where the alkyl group maybe linear or branched (e.g., -CH₂-CO-methyl or -CH₂-CO-ethyl);

The invention further features compounds of formula lb

wherein each of R¹, R², R³ and R⁴ has been defined in formula I above, and wherein

„b • R is

(i) -CO-(Cι-C₆ alkyl) where the alkyl group maybe linear or branched (e.g., -CO-methyl or -CO-ethyl); or

(ii) hydrogen. Within the scope of the invention are also pharmaceutically and pharmacologically acceptable salts of a compound of formula I, formula la, and formula lb, as well as hydrates thereof. Some specific examples of R in accordance with the present invention are hydrogen, methoxy, ethoxy, propoxy, butoxy, pentoxy, and hexyloxy, wherein said alkoxy substituents may be linear or branched. Another specific example of R in accordance with the present invention is phenyl-(CH )_n-O- where n is an integer 1, or 2. Still another specific example of R in accordance with the invention is H N-CO-CH₂-

O-

2

Some specific examples of R in accordance with the present invention are hydroxy; methoxy, ethoxy, propoxy, butoxy, pentoxy, and hexyloxy, wherein said alkoxy substituents may be linear or branched; -O-CO-(CH₂)_n-CH₃ wherein n is an integer 0, 1, 2, 3, 4 or 5 (e.g., -O-CO-CH₂-CH₃); -O-CO-ρhenyl; and -O-CO-naphthyl. Some specific examples of R and R in accordance with the present invention are methyl, ethyl, propyl, butyl, pentyl, and hexyl, wherein the alkyl groups may be linear or branched; cyclopentyl; and cyclohexyl.

A specific example of R^a in accordance with the present invention is -CH₂-CO-(CH₂)_n-CH₃ wherein n is an integer 0, 1, 2, 3, 4 or 5 (e.g., -CH₂-CO-CH₂-CH₃, -CH₂-CO-(CH₂)₂-CH₃, or -CH₂-CO-(CH₂)₃-CH₃).

A specific example of R in accordance with the present invention is -CO-(CH₂)_n-CH₃ wherein n is an integer 0, 1, 2, 3, 4 or 5 (e.g., -CO-CH₃, -CO-CH₂- CH₃, or -CO-(CH₂)₂-CH₃). A subset of the compounds of the invention include compounds of formula I, formula la, or formula lb wherein R is linear or branched -C₆ alkoxy, phenyl-(CH₂)_n-O- where n is an integer 1 or 2, or H₂N-CO-CH₂-O-; and R is linear or branched Cι-C₆ alkoxy, -O-CO-(CH )_n-CH₃ where n is an integer 0, 1, 2, 3, 4 or 5, -O- CO-phenyl, or -O-CO-naphthyl. Another subset of compounds of the invention include compounds of formula I, formula la, or formula lb wherein R is hydrogen, linear or branched Cι-C₆ alkoxy, phenyl-(CH₂)_n-O- where n is an integer 1 or 2, or H₂N-CO-CH₂-

2

O-; R is hydroxy, linear or branched Cι-C alkoxy, or -O-CO-(CH )_n-CH₃ where n is an integer 0, 1, 2, or 3; and R³ and R⁴ are each and independently linear or branched Cι-C₃ alkyl. Still another subset of the invention include compounds of formula I, formula la, or formula lb wherein R is hydrogen, linear or branched ethoxy, propoxy, or butoxy; phenyl-(CH₂)_n-O- where n is an integer 1 or 2; or H₂N-CO-CH₂-O-; R is hydroxy; methoxy, -O-CO-CH₃; R³ and R⁴ are each methyl; R^a is -CH₂-CO-CH₃; and R^b is -CO- CH_3.

The compounds according to the present invention are useful in therapy, particularly for the treatment of type 2 diabetes mellitus. Also within the scope of the invention is the use of a compound of the formula I, for the manufacture of a medicament for the treatment of type 2 diabetes mellitus.

A further aspect of the invention is the use of a compound of the formula la, for the manufacture of a medicament for the treatment of type 2 diabetes mellitus.

Still a further aspect of the invention is the use of a compound of the formula lb, for the manufacture of a medicament for the treatment of type 2 diabetes mellitus.

A further aspect of the invention is a method for the treatment of a patient suffering from type 2 diabetes mellitus, whereby an effective amount of a compound according to formula I above, is administered to a patient in need of such treatment.

A further aspect of the invention is a method for the treatment of a patient suffering from type 2 diabetes mellitus, whereby an effective amount of a compound according to formula la above, is administered to a patient in need of such treatment.

Still a further aspect of the invention is a method for the treatment of a patient suffering from type 2 diabetes mellitus, whereby an effective amount of a compound according to formula lb above, is administered to a patient in need of such treatment.

Definitions

As used herein, an alkyl is a straight or branched hydrocarbon chain containing the indicated number of carbon atoms. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, n- pentyl, 2-methylpentyl, and n-hexyl.

By cycloalkyl is meant a cyclic alkyl group containing the indicated number of carbon atoms. Some examples of cycloalkyl are cyclopropyl, cyclopentyl, cyclohexyl, adamantyl, and norbornyl. Heterocycloalkyl is a cycloalkyl group containing the indicated number of heteroatoms such as nitrogen, oxygen, or sulfur. Examples of heterocycloalkyl include piperidinyl, piperazinyl, tetrahydropyranyl, tetrahydrofuryl, and morpholinyl. As used herein, aryl is an aromatic group containing the indicated number of ring atoms. Examples of an aryl group include phenyl, naphthyl, phenanthryl, and anthracyl. Heteroaryl is aryl containing the indicated number of heteroatoms such as nitrogen, oxygen, or sulfur. Some examples of heteroaryl are pyridyl, furanyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, and imidazolyl.

Each of the cycloalkyl, heterocycloalkyl, aryl, or heteroaryl groups described herein is optionally substituted with Cι-₄ alkyl, C₃.₆ cycloalkyl, 3-6 membered heterocycloalkyl, C₆-₁₀ aryl, 6-10 membered heteroaryl, C .₁ aralkyl, Cι.₄ alkyl- heteroaryl with 6-10 ring atoms, C₁.₄ alkoxy, hydroxy, hydroxyl-C₁-₄ alkyl, carboxyl, halo, halo-Cι-₄ alkyl, amino, amino-Cι-₄ alkyl, nitro, cyano, C1-5 alkylcarbonyloxy,

Cι-5 alkyloxycarbonyl, C1-5 alkylcarbonyl, formyl, oxo, aminocarbonyl,

C1-5 alkylcarbonylamino, Cμ alkylsulfonylamino, aminosulfonyl, ammocarbonyloxy, or

Ci_₄ alkyloxycarbonylamino. Note that an amino group can be unsubstituted, mono-substituted, or di- substituted. It can be substituted with groups such as Cι-₄ alkyl, C₃-₆ cycloalkyl, 3-6 membered heterocycloalkyl, C₆-₁₀ aryl, or 6-10 membered heteroaryl. Halo refers to fluoro, chloro, bromo, or iodo.

Methods of Preparation

The compounds according to the present invention may be prepared as described by the following methods.

The compounds of formula I can be synthesized from the corresponding 5 and 6- hydroxyquinone according to the procedure reported by Ley and Nast Angew. Chem. 1967, 79, 150 (see Schemes 1 and 2 below). The starting material 5-hydroxyquinone is commercially available from Aldrich. Another starting material silver oxide can be prepared according to a literature procedure (Vogel's textbook of practical Organic Chemistry 5ⁿ Edition, p677) and stored under inert atmosphere in the dark until used. Freshly prepared silver oxide generally gives the best results. SCHEME 1

SCHEME 2

The invention will now be described in more details in the following Examples, which however should not be construed as limiting the invention. In the following examples, column chromatography was carried out using either normal glass columns and compressed air or pumps and fractions collectors. The packing materials used were Merck Silica Gel 60 (230-400 mesh) or YMC-GFL Silica 6θA S-50 Mesh. 1H NMR and ¹³C NMR were recorded on a Varian at 500 MHz and at 125.7 MHz, respectively.

H NMR and C NMR spectra were referenced to residual solvent or to tetramethylsilane as internal standard. El MS spectra were obtained on Micromass Quattro I instrument. Elementary analyses were performed at a Nario EL instrument (Elementar Analysensysteme GmbH, Hanau, Germany). EXAMPLES

I) Preparation of 6-Hvdroxynaphthoqιιinone (compound 2)

1,6-Dihydroxynaphtalene from Aldrich (3.0 g, 18.7 mmol) was dissolved in a mixture of MeOH (150 mL), KH₂PO -solution (0.167 M, 150 mL) and water (200 mL), and Potassium nitrosodisulfonate (Fremy's salt) (12.0 g, 44.7 mmol) was added. The mixture was stirred at room temperature 2 h. The reaction mixture was put in refrigerator and then filtered. Yield 3.0g. 1H NMR (400 MHz, CD₃OD) δ 6.90 (d, 2 H), 7.12 (dd, 1 H), 7.34 (d, 1 H), 7.92 (d, 1 H).

II) Preparation of 2-(6-Hydroxy-l,4-dioxo-l,4-dihydro-2-naphthalenyl)-2- methylpropanal (compound 3)

6-Hydroxynaphthoquinone (compound 2 prepared in step I above) (0.74 g, 2.35 mmol) was dissolved in 75% MeOH (30 mL) and powdered FeCl₃ ^• 6H₂O (1.65 g, 6.1 mmol) was added. The mixture was stirred for 4 h. The solvent was evaporated and the crude product (compound 3) was purified on silica gel with hexane:EtOAc 4:1. Yield: 0.27 g (47 %). 1H NMR (400 MHz, Acetone-^) δ 1.36 (s, 6 H), 6.90 (s, 1 H), 7.24 (dd, 1 H), 7.39 (d, 1 H), 7.94 (d, 1 H), 9.64 (s, 1 H). III) Preparation of 2-(5-Hydroxy-l,4-dioxo-l,4-dihvdro-2-naphthalenyl)-2- methylpropanai (compound 4)

Compound 4 was prepared from 5-hydroxyquinone according to the procedure used for the preparation of compound 3. Yield: 2.11 g (60 %). 1H NMR (400 MHz, CDC1₃) δ 1.43 (s, 6 H), 6.91 (s, 1 H), 7.27 (m, 1 H), 7.60-7.68 (m, 2 H), 9.72 (s, 1 H), 11.76 (s, l H).

EXAMPLE 1

Preparation of 7-Butoxy-4-hydroxy-3,3-dimethyI-2H-benzofg1indole-2,5(3H)-dione

(compound 7)

Step (i): Preparation of 2-(6-Butoxy- 1 ,4-dioxo- 1 ,4-dihvdro-2-naphthalenyl -2- methylpropanal (compound 5)

A mixture of 2-(6-Hydroxy-l,4-dioxo-l,4-dihydro-2-naphthalenyl)-2- methylpropanal (compound 3 prepared in step II above) (125 mg, 0.52 mmol) and freshly prepared Ag₂O (240 mg, 1.04 mmol) in CH₃CN was ultrasonicated for 2 min to disperse the silver salt. Iodobutane (120 μL, 1.05 mmol) was added and the mixture was stirred over night at room temperature. The mixture was filtered on Celite and was washed with EtOAc. The crude product was purified on silica gel with hexane:EtOAc 4: 1 but failed to yield pure material. The product was further purified on RP-HPLC. Yield: 53 mg (34%). 1H NMR (400 MHz, CDC1₃) δ 0.99 (tr., 3 H), 1.40 (s, 6 H), 1.52 (sext, 2 H), 1.82 (quint., 2 H), 4.11 (tr., 2 H), 6.87 (s, 1 H), 7.18 (dd, 1 H), 7.48 (d, 1 H), 8.00 (dd, 1 H), 9.72 (s, 1 H).

Step (ii): Preparation of 7-Butoxy-2-hvdroxy-3,3-dimethyl-2.3-dihvdro-5H- benzo[g]indol-5-one 1-oxide (compound 6)

To a solution of 2-(6-Butoxy-l,4-dioxo-l,4-dihydro-2-naphthalenyl)-2- methylpropanal (compound 5 prepared in step (I) above) (53 mg, 0.18 mmol) in MeOH (5 mL) and water (0.5 mL), 50% NH₂OH in water solution (17 μL, 0.28 mmol) was added. The mixture was stirred 3 h at room temp and the solvent was evaporated. The crude product was fairly pure and was taken into the next step without further purification. Yield: 52 mg (92%). 1H NMR (400 MHz, CDC1₃) δ 0.99 (tr., 3 H), 1.38 (s, 3 H), 1.52 (s, 3 H), 1.55 (m, 2 H), 1.84 (quint., 2 H), 4.13 (tr., 2 H), 5.31 (s, 1 H), 6.43 (s, 1 H), 7.24 (d, 1 H), 7.73 (d, 1 H), 9.07 (d, 1 H).

Step (iii): Preparation of the title compound 7-Butoxy-4-hvdroxy-3,3-dimethyl-2H- benzo[^"g^~|indole-2.5(3H)-dione (compound 7)

A solution of 7-Butoxy-2-hydroxy-3,3-dimethyl-2,3-dihydro-5H-benzo[g]indol- 5-one 1-oxide (compound 6 prepared in step (ii) above)(13 mg, 0.036 mmol) in EtOH (2 mL) with cone. HCl in EtOH (0.5 mL) was heated at 60° for 1 h. The yellow solution turned red. When no starting material remained, benzoquinone (39 mg, 0.36 mmol) was added and the mixture was heated 1 h. The solvent was evaporated and the crude product was purified on RP-HPLC. Yield. 12 mg. (24 %). 1H NMR (400 MHz, CDC1₃) δ 1.00 (tr., 3 H), 1.51 (m, 2 H), 1.55 (s, 6 H), 1.82 (m, 2 H), 4.10 (tr., 2 H), 7.20 (dd, 1 H), 7.46 (d, 1 H), 7.70 (d, 1 H), 9.62 (br.s, 1 H). MS (El) m/z 313 (M⁺).

EXAMPLE 2

Preparation of 9-(Benzyloxy)-4-hvdroxy-3,3-dimethyl-2H-benzo[g1indole-2,5(3H)- dione (compound 10)

Compound 10 was prepared according the procedure described for Example 1.

Step (i): Preparation of 2- 8-(Benzyloxy)-l,4-dioxo-1.4-dihydro-2-naphthalenyl]-2- methylpropanal (compound 8)

Benzyl bromide was used as reagent. Yield: 209 mg (62%). 1H NMR (400 MHz, Acetone-^) δ 1.37 (s, 6 H), 5.35 (s, 2 H), 6.89 (s, 1 H), 7.31 (m, 1 H), 7.39 (tr, 2 H), 7.61 (m, 3 H), 7.66 (d, 1 H), 7.77 (m, 1 H), 9.65 (s, 1 H). Step (ii): Preparation of 9-(Benzyloxy -2-hvdroxy-3.3-dimethyl-2.3-dihydro-5H- benzo[g^~|indol-5-one 1-oxide compound 9)

Yield: 70 mg (40%). 1H NMR (400 MHz, CDC1₃) δ 1.36 (s, 3 H), 1.46 (s, 3 H), 5.37 (s, 2 H), 5.77 (br.s, 1 H), 6.38 (s, 1 H), 7.30 (d, 1 H), 7.37 (m, 3 H), 7.56 (m, 3 H), 7.88 (d, 1 H).

Step (iii): Preparation of the title compound 9-(Benzyloxy -4-hvdroxy-3,3-dimethyl- 2H-benzo[g]indole-2,5(3H)-dione (compound 10)

Yield: 37 mg (62 %). 1H NMR (400 MHz, CDC1₃) δ 1.48 (s, 6 H), 5.31 (s, 2 H), 7.31 (d, 1 H), 7.44 (m, 5 H), 7.53 (tr, 1 H), 7.85 (d, 1 H), 8.98 (br.s, 1 H). MS (El) m/z 347 (M^1")

EXAMPLE 3

Preparation of 4-Hydroxy-9-isobutoxy-3,3-dimethyl-2H-benzofg1indole-2,5(3H)- dione (compound 13)

Compound 13 was prepared according the procedure used for Example 1. Iodo-2-methylpropane was used as reagent.

Step (i): Preparation of 2-(8-Isobutoxy- 1 ,4-dioxo- 1 ■4-dihydro-2-naphthalenyl -2- methylpropanal (compound 11)

Yield: 120 mg (40%). 1H NMR (400 MHz, CDC1₃) δ 1.07 (s, 3 H), 1.09 (s, 3 H), 1.38 (s, 6 H), 2.21 (sept., 1 H), 3.88 (d, 2 H), 6.83 (s, 1 H), 7.28 (dd, 1 H), 7.64 (tr, 1 H), 7.68 (dd, 1 H), 9.69 (s, 1 H).

Step (ii): Preparation of 2-Hvdroxy-9-isobutoxy-3.3-dimethyl-2,3-dihvdro-5H- benzo[^"g^~|indol-5-one 1-oxide (compound 12)

Yield: 27 mg (25%). 1H NMR (400 MHz, CDC1₃) δ 0.99 (s, 3 H), 1.01 (s, 3 H), 1.31 (s, 3 H), 1.43 (s, 3 H), 2.21 (nonett, 1 H), 3.82 (dd, 1 H), 3.91 (dd, 1 H), 5.21 (s, 1 H), 6.31 (s, 1 H), 7.15 (d, 1 H), 7.50 (tr, 1 H), 7.78 (dd, 1 H). Step (iii): Preparation of the title compound 4-Hvdroxy-9-isobutoxy-3.3-dimethyl-2H- benzo|^"g^"lindole-2.5(3H)-dione (compound 13)

Yield. 8 mg (30 %). 1H NMR (400 MHz, CDC1₃) δ 1.12 (s, 3 H), 1.14 (s, 3 H), 1.52 (s, 6 H), 2.27 (nonett, 1 H), 4.00 (d, 1 H), 7.24 (dd, 1 H), 7.55 (tr, 1 H), 7.85 (dd, 1 H), 8.97 (br.s, 1 H). MS (El) m/z 313 (M⁺)

EXAMPLE 4

Preparation of 4-Hvdroxy-3,3-dimethyl-9-(2-phenyIethoxy)-2H-benzofglindole-

2,5(3H)-dione (compound 16)

16

Compound 16 was prepared according the procedure used for Example 1. Step (i): Preparation of 2-ri.4-Dioxo-8-(2-phenylethoxy)-l,4-dihvdro-2-naphthalenyll- 2-methylpropanal (compound 14)

(2-Iodoethyl) benzene was used as reagent. Yield: 100 mg (35%). 1H NMR

(400 MHz, CDC1₃) δ 1.39 (s, 6 H), 3.20 (tr, 2 H), 4.29 (tr., 2 H), 6.83 (s, 1 H), 7.23 (m, 2 H), 7.31 (m, 3 H), 7.35 (m, 1 H), 7.60 (tr., 1 H), 7.67 (dd, 1 H), 9.71 (s, 1 H). Step (ii): Preparation of 2-Hvdroxy-3,3-dimethyl-9-(2-phenylethoxy)-2,3-dihvdro-5H- benzo|^"g^~|indol-5-one 1-oxide (compound 15)

Yield: 13 mg (14%). 1H NMR (400 MHz, CDC1₃) δ 1.38 (s, 3 H), 1.47 (s, 3 H), 3.24 (m, 2 H), 4.32 (m, 1 H), 4.43 (m, 1 H), 5.27 (s, 1 H), 6.35 (s, 1 H), 7.22 (m, 1 H), 7.26-7.39 (m, 5 H), 7.54 (tr., 1 H), 7.84 (d, 1 H).

Step (iii): Preparation of the title compound 4-Hydroxy-3.3-dimethyl-9-(2- phenylethoxy)-2H-benzo glindole-2,5(3H)-dione (compound 16) Yield. 5 mg. (40%). 1H NMR (400 MHz, CDC1₃) δ 1.46 (s, 6 H), 3.23 (tr., 2 H),

4.50 (tr., 2 H), 7.26 (dd, 1 H), 7.33 (m, 3 H), 7.42 (m, 2 H), 7.54 (tr., 1 H), 7.82 (dd, 1 H), 8.71 (br. s, 1 H). MS (El) m/z 361 (M⁺)

EXAMPLE 5 Preparation of 4-Hydroxy-9-ethoxy-3,3-dimethyl-2H-benzofg1indole-2,5(3H)-dione (compound 19)

Compound 19 was prepared according the procedure used for Example 1. Step (i): Preparation of 2-(8-ethoxy- 1 ,4-dioxo- 1 ,4-dihydro-2-naphthalenyl)-2- methylpropanal (compound 17)

Iodoethane was used as reagent. Yield: 380 mg (93%). 1H NMR (400 MHz, CDC1₃) δ 1.38 (s, 6 H), 1.43 (t, 3H), 3.89 (q, 2 H), 6.83 (s, 1 H), 7.28 (dd, 1 H), 7.64 (tr, 1 H), 7.68 (dd, 1 H), 9.69 (s, 1 H).

Step (ii): Preparation of 2-Hvdroxy-9-ethoxy-3,3-dimemyl-2,3-dihvdro-5H- benzo|^"g^"|indol-5-one 1-oxide (compound 18)

Yield: 130 mg (60%). 1H NMR (400 MHz, CDC1₃) δ 1.31 (s, 6 H), 1.35 (t, 3 H), 3.87 (q, 2 H), 5.21 (d, 1 H), 6.31 (s, 1 H), 7.15 (d, 1 H), 7.50 (tr, 1 H), 7.78 (dd, 1 H).

Step (iii): Preparation of the title compound 4-Hvdroxy-9-ethoxy-3,3-dimethyl-2H- benzo|^"g^"jindole-2,5(3H)-dione (compound 19)

Yield. 65 mg (30 %). 1H NMR (400 MHz, CDC1₃) δ 1.36 (s, 6 H), 1.37 (s, 3H), 3.90 (q, 1 H), 7.24 (dd, 1 H), 7.55 (tr, 1 H), 7.85 (dd, 1 H), 8.97 (br.s, 1 H). MS (El) m/z 285 (M⁺) EXAMPLE 6

Preparation of 2- r(4-Hvdroxy-3,3-dimethyl-2,5-dioxo-3,5-dihvdro-2H- benzofg1indol-9-yl)oxy1acetamide (compound 22)

22

Compound 22 was prepared according the procedure used for Example 1.

Step (i): Preparation of 2- { [7-( 1 , 1 -Dimethyl-2-oxoethyl)-5 , 8-dioxo-5.8-dihydro- 1 - naphthalenyl]oxy>acetamide (compound 20)

20

Acrylamide was used as reagent. Yield: 67 mg (27%). 1H NMR (400 MHz, Acetone-^) δ 1.38 (s, 6 H), 4.63 (s, 2 H), 6.95 (s, 1 H), 7.56 (d, 1 H), 7.73 (d, 1 H), 7.86 (tr., 1 H), 9.65 (s, 1 H).

Step (ii): Preparation of 2-[(2-Hvdroxy-3.3-dimethyl- 1 -oxido-5-oxo-3 ,5-dihydro-2H- benzo g]indol-9-yl)oxy1acetamide (compound 21)

Yield: 70 mg crude product has been used to obtain the final compound. MS (El) m/z 314 (M÷)

Step (iii): Preparation of the title compound 2-[(4-Hvdroxy-3.3-dimethyl-2,5-dioxo-3,5- dihydro-2H-berιzo[glindol-9-yl)oxy]acetamide (compound 22)

Yield: 7 mg. (10 %). 1H NMR (400 MHz, DMSO-^) δ 1.34 (s, 6 H), 4.83 (s, 2 H), 7.36 (tr., 1 H), 7.54 (br.s, 1 H), 7.67 (m, 2 H), 7.77 (br.s, 1 H), 11.25 (br.s, 1 H). MS (El) m/z 314 (M⁺)

EXAMPLE 7

Preparation of 4-methoxy-3,3-dimethyl-2H-benzo[g1indole-2,5(3H)-dione

(compound 23)

To a solution of 4-hydroxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dione (compound 1) (0.1 g, 0.415 mmol) in MeOH (5 mL) was added K₂CO₃ (0.132 g, 0.96 mmol) while stirring at RT. After 10 min. Mel (100 μL, 0.228 g, 1.6 mmol) was added via a syringe and the mixture was allowed to stirred over night. The solvent was removed in vacuum and the solid was dissolved in CHC1 , filtered and purified by prep. HPLC (SF/ CHC1₃). Yield: 0.051 mg (50%). 1H NMR (400 MHz, CDC1₃) δ 1.48 (s, 6 H), 3.68 (s, 3 H), 7.58 (t, 1 H), 7.68 (t, 1 H), 8.02 (d, 1 H), 8.23 (d, 1 H). MS (CI) m/z: 256.31 (M+l).

EXAMPLE 8 Preparation of 4-methoxy-3,3-dimethyl-4-(2-oxopropyl)-lH-benzo g] indole- 2,5(3H.4H)-dione (compound 24)

To a solution of 4-hydroxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dione (compound 1) (0.1 g, 0.415 mmol) in acetone (5 mL) was added K₂CO₃ (0.132 g, 0.96 mmol) while stirring at RT. After 10 minutes, Mel (0.058 g, 0,41 mmol) was added via a syringe and the mixture was allowed to stir for 1 h followed by addition of more Mel (0.058 g, 0,41 mmol) and the reaction was stirred over night. The solvent was removed in vacuum and the solid was dissolved in CHC1₃, filtered and purified by preparative HPLC. Yield: 64 mg (50%). 1H NMR (400 MHz, CDC1₃) δ 1.46 (d, 6 H), 2.12 (s, 3 H), 2.90 (s, 2 H), 3.65 (s, 3 H), 7.42 (t, 1 H), 7.55 (t, 1 H), 7.78 (d, 1 H), 7.94 (d, 1 H).: MS (CI) m/z 314.36 (M+l).

EXAMPLE 9

Preparation of 4-(acetyloxy)-3,3-dimethyl-2-oxo-2,3-dihydro-lH-benzo [gl indol-5-yl acetate (compound 25)

25 To a solution of 4-hydroxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dione (0.030 g, 0.124 mmol) in z^'-PrOH (0.5 mL) was added NaBH₄ (0.020 g, 0.52 mmol) while stirring at RT. After 5 minutes, Ac₂O (100 μL, O.lg, 0,98 mmol) was added via a syringe and the mixture was allowed to stir for 1 h followed by addition of more NaBH₄ (0.020 g, 0.52 mmol) and stirring over night. The solvent was removed in vacuum and the solid was dissolved in CHC1₃, filtered and purified by prep. HPLC (RP). Yield: 0.016 mg (40%). 1H NMR (400 MHz, CDC1₃) δ 1.50 (brs, 6 H), 2.35 (appd, 6 H), 7.47 (m, 2 H), 7.68 (d, 1 H), 7.85 (d, 1 H), 10.05 (brs, 1H). MS (CI) m/z: 328.36 (M+l).

Pharmaceutical Compositions

The novel compounds according to the present invention may be administered orally, intranasally, transdermally, subcutaneously, parenterally, intramusculary, as well as intravenously. Oral administration is the preferred route.

The dosage will depend on the route of administration, the severity of the disease, age and weight of the patient, and other factors normally considered by the attending physician when determining the individual regimen and dosage level as the most appropriate for a particular patient.

Either solid or fluid dosage forms can be prepared for oral administration. Solid compositions, such as compressed tablets, are prepared by mixing the compounds of the invention with conventional ingredients such as talc, magnesium stearate, dicalcium phosphate, magnesium aluminum silicate, calcium sulfate, starch, lactose, acacia, methyl cellulose, or functionally similar pharmaceutical diluents and carriers. Capsules are prepared by mixing the compounds of this invention with an inert pharmaceutical diluent and placing the mixture into an appropriately sized hard gelatin capsule. Soft gelatin capsules are prepared by machine encapsulation of a slurry of the compounds of this invention with an acceptable inert oil such as vegetable oil or light liquid petrolatum.

Syrups are prepared by dissolving compounds of the invention in an aqueous vehicle and adding sugar, aromatic flavoring agents and preservatives. Elixirs are prepared using a hydroalcoholic vehicle such as ethanol, suitable sweeteners such as sugar or saccharin and an aromatic flavoring agent. Suspensions are prepared with an aqueous vehicle and a suspending agent such as acacia, tragacanth, or methyl cellulose. When the compounds of the invention are administered parenterally, they can be given by injection or by intravenous infusion. Parenteral solutions are prepared by dissolving the compounds of the invention in aqueous vehicle and filter sterilizing the solution before placing in a suitable sealable vial or ampule. Parenteral suspensions are prepared in substantially the same way except a sterile suspension vehicle is used and the compounds of the present invention are sterilized with ethylene oxide or suitable gas before it is suspended in the vehicle.

Thus, a further aspect of the present invention is a pharmaceutical composition comprising a compound of formula I, formula la, or formula lb, supra, as active ingredient, together with a pharmacologically and pharmaceutically acceptable carrier. It is preferred to use pharmaceutically inert carriers which may be solid or liquid. Solid form preparations include but is not limited to powders, tablets, dispersible granules, capsules etc. A skilled person within the formulation field will readily know which carrier to use for the specific circumstance when formulating a composition in accordance with the present invention.

Pharmaceutically acceptable salts of a compound of formula I, formula la, or formula lb, supra, which are within the scope of the present invention, may be formed from organic and inorganic acids. Examples of such salts are hydrochloride salts, tosylate salts, citrate salts, maleate salts, acetate salts, hydrobromide salts, malate salts, stearate salts, aluminium salts, lithium salts, calcium salts, and magnesium salts. This list should however not in any way be regarded as exhaustive. The hydrochloride salts are preferred.

Biological Evaluation

The compound 4-hydroxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dione, which is commercially available from Labotest in Germany, was tested for the medical indications claimed herein, together with other compounds within the scope of the present invention. Methods

Expression and purification ofrecombinant human PTPs

Human PTP1B (amino acid residues 1-298, cloned from a human placental library), without the GST tag and thrombin cleavage site, was inserted into a pMB replicon and transformed into E. coli BL21(DE3), a strain containing a chromosomal copy of the gene for T7 RNA polymerase under control of a lacUV5 promoter. Expression of PTP IB was induced with isopropyl thiogalactose and cells were lysed in lysis buffer comprising 50mM Tris-HCl pH 7.5, 10% glycerol, lmM EDTA, 3mM DTT, 3mM MgCl , and 0.2mg/ml lysozyme with lmg/ml DNAse I. The soluble protein was purified by ion exchange, hydrophobic interaction and gel exclusion chromatography for use in assays to identify PTP IB inhibitors. The plasmid pGEX2K- SHP2 which encoded the catalytic domain of human SHP-2 (residues 252-529) was used to transform E. coli cells. After induction of protein expression, cells were lysed in PBS containing 1% Triton XI 00 and lysozyme (2mg/ml). Recombinant protein was purified by glutathione sepharose 4B chromatography followed by Superdex 200 size exclusion chromatography. Recombinant proteins were stored at -70°C until used. Recombinant T cell PTP (TCPTP) and LAR were purchased from New England Biolabs.

Measurement of PTP activity

Human PTP IB activity was measured using p-nitrophenol phosphate (pNPP) as substrate in a 96-well microtiter plate format. An assay pH of 7.2 is used for standard assays (measured extinction coefficient =9800 at pH 7.2).

Standard assays were conducted at room temperature in a total volume of 0.2 ml that contains Hepes buffer (50 mM, pH 7.2), NaCl (50 mM), EDTA (1 mM), DTT (1 mM), bovine serum albumin (1 mg/ml), pNPP (1.25mM) and PTP IB (500ng/ml, 13.5nM). A master plate was set up for each compound in which a stock solution of compound in DMSO (19mM or lmM) was diluted 1 to 10 with assay buffer in column 1 (giving a lmM or 100 μM concentration). Substances were subsequently diluted serially by two thirds in all columns across the plate. For enzyme assays, 20 μl of each diluted compound was removed to a new plate and diluted to 200 μl (final volume) with 160 μl pNPP solution and 20 μl PTP IB solution. Reactions were thus started immediately and were stopped after 60 minutes by addition of 100 μl 0.1N NaOH. The OD⁴⁰⁵ was subsequently measured. Two wells on each plate contained DMSO controls and two wells contained sodium orthovanadate (2mM) which inhibits PTP IB-catalyzed hydrolysis of pNPP completely. Data were corrected for background absorbance by the subtraction of the optical densities from a no-enzyme control plate and were expressed as percent inhibition relative to the average of the vanadate controls measured on the same microtiter plate. The activity of the other PTPs was determined in a similar fashion except that the concentration of pNPP was varied according to the Km values for individual enzymes (0.6mM for TCPTP and 6.25mM for each of SHP-2 and LAR) and the buffer used for TCPTP was 25mM Tris-HCl pH 7.2.

Cell-based analysis of compound activity

The effects of compounds on the phosphorylation status of the insulin receptor was measured using L6 muscle cells expressing the receptor endogenously. L6 myocytes were cultured in -MEM with 10% foetal bovine serum and antibiotics. Cells were differentiated into myotubes in 24-well plates by culturing for 10 days in medium containing 2% serum. The medium was refreshed on alternate days and 0.24mg/ml cytidine was included from day 7 to stop any remaining cycling cells. Cells were starved of serum overnight prior to use. Cells were pretreated with compound at approximately five times the IC₅₀ for inhibition of PTP IB for 30 minutes, prior to being stimulated with insulin (25nM) for five minutes. Cells were lysed in buffer comprising 25mM Tris-HCl pH 7.4, 150mM NaCl, lmM EDTA, lmM EGTA, 1% Nonidet-40, 0.25% sodium deoxycholate, lmM sodium orthovanadate, lOmM β-glycerophosphate, 5mM sodium pyrophosphate and protease inhibitors. Cleared lysates were stored at - 70°C until used.

Insulin receptor phosphorylation was assessed using a lanthanide-based fluorescent assay (DELFIA). An anti-insulin receptor antibody was captured on the wells of a 96-well plate using an anti-rabbit IgG antibody. After incubation with lysates containing between 100-250μg protein which was consistent for all wells in a single experiment, phosphate on the receptor was detected with a biotinylated anti- phosphotyrosine antibody (PY99B from Santa Cruz) and europium-labelled streptavidin.

Results IC₅₀ values were determined for all compounds against each of four PTPs

(PTP IB, SHP-2, LAR and TCPTP). Compounds were active across a wide range of concentrations from lOOnM to 50μM.

Representative compounds from across the series were analysed in cell-based assays in which effects on insulin-stimulated auto-phosphorylation of the insulin receptor was determined. Compounds caused statistically significant increases in receptor phosphorylation by about 20% to about 70%.

Claims

1. A compound of formula I, formula la, or formula lb

wherein R* is

(i) hydrogen;

(ii) linear or branched Cι-C₆ alkoxy;

(ii) -O-(Ci-C₆ alkyl)-Q, where the alkyl group is linear or branched, and Q is phenyl, naphthyl, or a heterocycle having 5 to 10 ring atoms, where at least one of the ring atoms is O, N, or S; (iv)

O

Q \

N- C (CH₂)_n— O-

Q² where n is an integer 1 or 2, and each of Q¹ and Q² is independently hydrogen or d-C₆ alkyl, where the alkyl group is linear or branched; or (V) o

CH₃— O— C— (CH₂) -0—

where n is an integer 1 or 2;

R² is (i) hydroxy;

(ii) linear or branched Ci-C₆ alkoxy;

(iii) -O-CO-(C₁-C₆ alkyl), where the alkyl group is linear or branched; or

(iv) -O-CO-phenyl or -O-CO-naphthyl;

each of R³ and R⁴ is independently

(i) linear or branched C C₆ alkyl; or (ii) cyclopentane or cyclohexane;

R is -CH₂-CO-(C₁-C₆ alkyl), where the alkyl group is linear or branched; and

rib •

(i) -CO-(C₁-C₆ alkyl), where the alkyl group is linear or branched; or (ii) hydrogen;

provided that the compound 4-hydroxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dione is excluded; or a pharmaceutically and pharmacologically acceptable salt or hydrate thereof.

2. The compound of claim 1, said compound having formula I.

3. The compound of claim 1, said compound having formula la.

4. The compound of claim 1, said compound having formula lb.

5. The compound of claim 1, wherein

R is linear or branched CrC₆ alkoxy, phenyl-(CH₂)_n-O- where n is an integer 1 or 2, or H₂N-CO-CH₂-O-; and

R is linear or branched Ci-C₆ alkoxy, -O-CO-(CH₂)_n-CH₃ where n is an integer 0, 1, 2, 3, 4 or 5, -O-CO-phenyl, or -O-CO-naphthyl.

6. The compound of claim 1, wherein

2 2

RR iiss hhyyddrrooxxyy,, lliinneeεar or branched Ci-C₃ alkoxy, or -O-CO-(CH₂)_n-CH₃ where n is an integer 0, 1, 2, or 3.

2

7. The compound of claim 6, wherein R is hydroxy.

8. The compound of claim 6, wherein

R is hydrogen, linear or branched Ci-C₆ alkoxy, phenyl-(CH₂)_n-O- where n is an integer 1 or 2, or H₂N-CO-CH₂-O-; and each of R³ and R⁴ is independently linear or branched Ci-C₃ alkyl.

9. The compound of claim 1, wherein

R is hydrogen, linear or branched ethoxy, propoxy, or butoxy; phenyl-(CH₂)_n-O- where n is an integer 1 or 2; or H N-CO-CH₂-O-;

2

R is hydroxy, methoxy, or -O-CO-CH₃; and

3 4

R and R are each methyl.

10. The compound of claim 1, wherein R^a is -CH -CO-(CH₂)_n-CH₃ where n is an integer 0, 1, 2, 3, 4 or 5.

a

11. The compound of claim 1, wherein R is -CH₂-CO-CH₃.

12. The compound of claim 1, wherein R is -CO-(CH₂)_n-CH₃ where n is an integer 0, 1, 2, 3, 4 or 5.

13. The compound of claim 1, wherein R is -CO-CH .

14. The compound of claim 1, said compound being:

7-butoxy-4-hydroxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dione (compound 7); 9-(benzyloxy)-4-hydroxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dione (compound 10); 4-hydroxy-9-isobutoxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dione (compound 13);

4-hydroxy-3,3-dimethyl-9-(2-phenylethoxy)-2H-benzo[g]indole-2,5(3H)-dione

(compound 16);

4-hydroxy-9-ethoxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dione (compound 19);

2-[(4-hydroxy-3,3-dimethyl-2,5-dioxo-3,5-dihydro-2H-benzo[g]indol-9- yl)oxy]acetamide (compound 22);

4-methoxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dione (compound 23);

4-methoxy-3 ,3 -dimethyl-4-(2-oxopropyl)- 1 H-benzo [g] indole-2,5 (3H,4H)-dione

(compound 24); or

4-(acetyloxy)-3,3-dimethyl-2-oxo-2,3-dihydro-lH-benzo[g]indol-5-yl acetate (compound 25).

15. A hydrochloride salt or tosylate salt of a compound of claim 1.

16. A hydrochloride salt of a compound of claim 1.

17. A hydrochloride salt of a compound of claim 9.

18. A hydrochloride salt of a compound of claim 14.

19. A pharmaceutical composition comprising a compound of claim 1 and a pharmacologically and pharmaceutically acceptable carrier.

20. A pharmaceutical composition comprising a compound of claim 9 and a pharmacologically and pharmaceutically acceptable carrier.

21. A pharmaceutical composition comprising a compound of claim 14 and a pharmacologically and pharmaceutically acceptable carrier.

22. Use of a compound of formula I, formula la, or formula lb:

wherein

R* is (i) hydrogen;

(ii) linear or branched Cι-C₆ alkoxy; (ii) -O-(Ci-C₆ alkyl)-Q, where the alkyl group is linear or branched, and Q is phenyl, naphthyl, or a heterocycle having 5 to 10 ring atoms, where at least one of the ring atoms is O, N, or S; (iv)

1 O

^Q\ II

N— C (CH₂)_n— O

Q² where n is an integer 1 or 2, and each of Q and Q is independently hydrogen or Cι-C₆ alkyl, where the alkyl group is linear or branched; or (v)

O

II

CH₃— O— C— (CH₂) -O—

where n is an integer 1 or 2;

R² is

(i) hydroxy;

(ii) linear or branched -C_ό alkoxy;

(iii) -O-CO-(C₁-C₆ alkyl), where the alkyl group is linear or branched; or (iv) -O-CO-phenyl or -O-CO-naphthyl;

each of R³ and R⁴ is independently (ii) linear or branched C C₆ alkyl; or (ii) cyclopentane or cyclohexane;

.a

R is -CH₂-CO-(Ci-C₆ alkyl), where the alkyl group is linear or branched; and R is (i) -CO-(CrC₆ alkyl), where the alkyl group is linear or branched; or (ii) hydrogen;

or a pharmaceutically and pharmacologically acceptable salt or hydrate thereof, in the manufacture of a medicament for the treatment of type 2 diabetes mellitus.

23. Use of a compoxmd according to claim 9 in the manufacture of a medicament for the treatment of type 2 diabetes mellitus.

24. Use of a compound according to claim 14 in the manufacture of a medicament for the treatment of type 2 diabetes mellitus.